Emmanuel Elalouf
Directeur des opérations chez Pangea Therapeutics Ltd.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Tuvik Beker | M | - |
Pangea Therapeutics Ltd.
Pangea Therapeutics Ltd. Medical/Nursing ServicesHealth Services Pangea Therapeutics Ltd. is an Israeli company that specializes in developing a proprietary tumor intelligence platform called Technology Enlight. The company is based in Tel Aviv, Israel. This platform enables a deeper understanding of how a tumor would respond to therapy by considering expression abnormalities, which are more common than actionable mutations. By combining these with tumor vulnerability maps, the platform uncovers many more clinically relevant insights than approaches based solely on genomic alterations. The company was founded by Eytan Ruppin, Eyal Gottlieb, Ze'ev Ronai. The CEO is Tuvik Beker. | - |
Eyal Schiff | M | - |
Pangea Therapeutics Ltd.
Pangea Therapeutics Ltd. Medical/Nursing ServicesHealth Services Pangea Therapeutics Ltd. is an Israeli company that specializes in developing a proprietary tumor intelligence platform called Technology Enlight. The company is based in Tel Aviv, Israel. This platform enables a deeper understanding of how a tumor would respond to therapy by considering expression abnormalities, which are more common than actionable mutations. By combining these with tumor vulnerability maps, the platform uncovers many more clinically relevant insights than approaches based solely on genomic alterations. The company was founded by Eytan Ruppin, Eyal Gottlieb, Ze'ev Ronai. The CEO is Tuvik Beker. | - |
Omri Amirav-Drory | M | - |
Pangea Therapeutics Ltd.
Pangea Therapeutics Ltd. Medical/Nursing ServicesHealth Services Pangea Therapeutics Ltd. is an Israeli company that specializes in developing a proprietary tumor intelligence platform called Technology Enlight. The company is based in Tel Aviv, Israel. This platform enables a deeper understanding of how a tumor would respond to therapy by considering expression abnormalities, which are more common than actionable mutations. By combining these with tumor vulnerability maps, the platform uncovers many more clinically relevant insights than approaches based solely on genomic alterations. The company was founded by Eytan Ruppin, Eyal Gottlieb, Ze'ev Ronai. The CEO is Tuvik Beker. | 3 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Israël | 3 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Emmanuel Elalouf
- Réseau Personnel